Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Apatinib plus SOX as Neoadjuvant Therapy in Local Advanced Gastric Cancer
ChiCTR-OPC-16010061Phase 2Completed
- Sponsor
- Ruijin Hospital
- Start
- Dec 2016
- Modality
- Small Molecules, Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of Rivoceranib in gastric cancer (GC), sponsored by Ruijin Hospital. Primary endpoint: Pathologic response rate. Started Dec 2016; status: completed.
02
Drugs
Rivoceranib
03
Conditions
gastric cancer (GC)
Beyond the preview
Go deeper on ChiCTR-OPC-16010061.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-OPC-16010061.